# Bristol-Myers Squibb (Canada)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/bristol-myers-squibb-canada/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 4 |
| Citations | 12,477 |
| City | Montreal |
| Country | CA |
| Description | Bristol-Myers Squibb (Canada) is a research organisation in Montreal, CA. OpenAlex records 216 works and 12,477 citations for it. 53 researchers list it as their most recent affiliation. |
| Homepage | http://www.bmscanada.ca/en |
| OpenAlex ID | https://openalex.org/I4210110605 |
| Region | Quebec |
| Researchers | 53 |
| ROR ID | https://ror.org/01r00g076 |
| Type | company |
| Works | 216 |

## University papers

- [Non-small cell lung cancer with <i>EGFR</i> exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes](https://scholariq.org/papers/non-small-cell-lung-cancer-with-i-egfr-i-exon-20-insertion-mutation-a-systematic/)
- [Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/health-related-quality-of-life-and-utility-outcomes-with-selinexor-in-relapsed/)
- [1362P Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis](https://scholariq.org/papers/1362p-clinical-and-real-world-outcomes-in-patients-with-epidermal-growth-factor/)
- [Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons](https://scholariq.org/papers/comparative-effectiveness-of-remestemcel-l-rknd-versus-ruxolitinib-in-pediatric/)
- [Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis](https://scholariq.org/papers/comparing-costs-and-consequences-of-eltrombopag-plus-ist-versus-ist-alone-for/)
- [PND110 SYMPTOMS, DELAYED DIAGNOSIS AND QUALITY OF LIFE (QOL) DETERIORATION - EXPLORING THE BURDEN OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)](https://scholariq.org/papers/pnd110-symptoms-delayed-diagnosis-and-quality-of-life-qol-deterioration/)
- [HSR19-082: Epidemiological Findings and Outcomes in Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations: A Meta-Analysis](https://scholariq.org/papers/hsr19-082-epidemiological-findings-and-outcomes-in-non-small-cell-lung-cancer/)
- [PF718 THE ECONOMIC AND HUMANISTIC BURDEN OF GRAFT‐VERSUS‐HOST DISEASE (GVHD) IN PEDIATRIC PATIENTS: A SYSTEMATIC LITERATURE REVIEW (SLR)](https://scholariq.org/papers/pf718-the-economic-and-humanistic-burden-of-graft-versus-host-disease-gvhd-in/)
- [PBI35 HEALTH TECHNOLOGY ASSESSMENT (HTA) REVIEW OF CELL &amp; GENE THERAPIES: THE ROAD TO REIMBURSEMENT](https://scholariq.org/papers/pbi35-health-technology-assessment-hta-review-of-cell-and-amp-gene-therapies-the/)
- [PND31 AMYOTROPHIC LATERAL SCLEROSIS (ALS) RESULTS IN HIGH DIRECT AND INDIRECT COSTS TO PATIENTS, CAREGIVERS, AND HEALTHCARE SYSTEMS](https://scholariq.org/papers/pnd31-amyotrophic-lateral-sclerosis-als-results-in-high-direct-and-indirect/)

## University researchers

- [D. Tomaras](https://scholariq.org/researchers/d-tomaras/)

## University top topics

Showing 8 of 24.

- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.